Confirm your location

Confirm you location or select from a list of countries in order to get in touch with your local Ottobock market. We will make sure you´re redirected to your selected site in the future so you´ll always be in the right place.

News | December 2023

New clinical evidence on the Exopulse Mollii Suit

New clinical evidence now shows that Exopulse Mollii Suit can deliver swift, significant, and sustained improvement in both patients’ mobility and pain levels (1). Exopulse Mollii Suit is a near-full-body neurostimulation garment designed to reduce spasticity and related pain with just an hour of wear time.

The recent Exopulse Mollii Suit study evaluated a total of 44 patients with multiple primary conditions, including cerebral palsy (CP, n=16, 7 pediatric), multiple sclerosis (MS, n=16), and stroke (n=12). All participants were at elevated risk of falls, as measured by the Berg Balance Scale (BBS < 45). Participants were evaluated at three timepoints: baseline (T0), after a single 60-minute stimulation session (T1), and after four weeks of home use (T2).

The results showed:

  • Significant functional improvement and reduced fall risk in all three cohorts after one hour of stimulation (increased BBS T0→T1).

  • Sustained improvement with regular use, with all three cohorts demonstrating improved mobility and decreased fall risk after 4 weeks q.o.d. stimulation (increased BBS T1→T2).

  • Significant reduction in spasticity-related pain after one hour of stimulation (reduction in EQ5D5L pain scores). This improvement was also sustained by regular stimulation.

The study also provided cohort-level evidence for the suit’s impact:

  • CP, MS, and stroke patients all showed significant and sustained reduction in pain at T0, T1, and T2.

  • CP patients showed significant improvement in balance and functional gait parameters.

  • MS patients showed significant improvements in balance, mobility, and quality of life (QoL).

  • Stroke patients highly benefit from the Exopulse Mollii Suit in terms of balance and QoL.

These results provide encouraging evidence for the Exopulse Mollii Suit’s impact on multiple key clinical parameters, especially fall risk and pain. With positive effects perceptible in just 60 minutes, easy and early identification of responders should make trial fittings even more attractive and effective.

(1) Hahn A, Moeller S, Schlausch A, Ekmann M, de Chelle G, Westerlund M, et al. “Effects of a full-body electrostimulation garment application in a cohort of subjects with cerebral palsy, multiple sclerosis and stroke on upper motor neuron syndrome symptoms”, 2023, Biomedical Engineering, doi: 10.1515/bmt-2023-0271.

Discover the Exopulse Mollii Suit

Intended for spasticity reduction, weak muscle activation and related pain relief

Find out more about the features and benefits of the Exopulse Mollii Suit.

Save and share

Exopulse Mollii Suit clinician brochure.

Take a snapshot of the technology, evidence, and start-up steps for your clinic.


The Exopulse Mollii Suit. (HQ)

Drug-free, non-invasive spasticity management with innovative near full-body neurostimulation.
Drug-free, non-invasive spasticity management with innovative near full-body neurostimulation.

1 results out of 1